Typhoid conjugate vaccine - Bharat Biotech
Alternative Names: Typbar-TCV; Typhoid conjugate vaccine (Typbar-TCV) - Bharat Biotech; Typhoid Vi capsular polysaccharide tetanus toxoid protein conjugate vaccine (Typbar-TCV) - BBIL; Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV) - Bharat Biotech; Typhoid Vi polysaccharide-TT conjugate vaccine - Bharat BiotechLatest Information Update: 30 Oct 2021
At a glance
- Originator Bharat Biotech
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Typhoid
Most Recent Events
- 03 Jan 2018 Bharat Biotech plans to launch typhoid conjugate vaccines in Gavi-supported countries in the first half of 2019
- 03 Jan 2018 World Health Organisation pre-qualifies typhoid conjugate vaccine for Typhoid
- 26 Aug 2013 Launched for Typhoid (prevention) in India (IM); first launch of Typbar-TCV™